Biological Pathways of Strength Preservation During Calorie Restriction-Induced Weight Loss Among Adults Without Obesity.

Obesity (Silver Spring)Sep 1, 2026 (epub)
Clinical ResearchEndocrinologyGeriatrics

Nadia Moore, Akshay Bareja, Leanna M Ross et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial analyzed the CALERIE study to identify molecular predictors of strength preservation during calorie restriction in healthy adults without obesity. Over 12 months, 151 genes were significantly associated with changes in knee extensor strength after adjusting for whole-body mass changes. Key genes included HSP90AA1 and EIF3A.

Key findings

  • 151 genes were significantly associated with changes in strength after accounting for whole-body mass change.
  • Key genes identified include HSP90AA1 and EIF3A.
  • Pathway analyses indicated involvement in cellular proliferation, immune regulation, and protein secretion.

Why it matters

Understanding the molecular mechanisms that support strength retention during weight loss can help clinicians develop strategies to preserve muscle mass and functional ability in patients undergoing caloric restriction.

Source

PubMed · PMID 42677907

Published in Obesity (Silver Spring). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.